跳到正文
Generate:Biomedicines· @generate_biomed · X·· 20 天前AI 评分59
AI 导读

Generate Biomedicines 称其六名科学家在与 Anthropic 的合作中,用 Claude 配合自研模型、计算工具和湿实验数据,重构了面向实体瘤的 CAR T 细胞受体。

正文 · 原文

A smaller CAR T-cell receptor could make room for a more capable therapy.

In our collaboration with @AnthropicAI, six of our scientists used @claudeai alongside our own models, computational tools, and wet lab data to refactor a CAR T-cell receptor for solid tumors.

The redesigned signaling component was about 70% shorter than a standard design, making room for new functions and improving cancer-cell killing in laboratory tests. Watch how our scientists turned years of work into months, at a fraction of the cost, expanding what we can engineer for patients.

@AnthropicAI's case study → https://www.anthropic.com/research/early-progress-drug-development

Our preprint → https://generatebiomedicines.com/publications/refactored-intracellular-domains-enhance-car-expression-and-function/

Our blog → https://generatebiomedicines.com/blog-posts/project-canele-an-effort-to-make-biotech-and-in-the-process-the-car-signaling-domain-simpler-smaller-and-more-effective/

来源:Generate:Biomedicines · x.com